Hubbry Logo
Left ventricular hypertrophyLeft ventricular hypertrophyMain
Open search
Left ventricular hypertrophy
Community hub
Left ventricular hypertrophy
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Left ventricular hypertrophy
Left ventricular hypertrophy
Left ventricular hypertrophy
View on Wikipedia
from Wikipedia
Left ventricular hypertrophy
A heart with left ventricular hypertrophy in short-axis view
SpecialtyCardiology
ComplicationsHypertrophic cardiomyopathy, Heart failure[1]
Diagnostic methodEchocardiography, cardiovascular MRI[1]
Differential diagnosisAthletic heart syndrome

Left ventricular hypertrophy (LVH) is thickening of the heart muscle of the left ventricle of the heart, that is, left-sided ventricular hypertrophy and resulting increased left ventricular mass.

Causes

[edit]

While ventricular hypertrophy occurs naturally as a reaction to aerobic exercise and strength training, it is most frequently referred to as a pathological reaction to cardiovascular disease, or high blood pressure.[2] It is one aspect of ventricular remodeling.

While LVH itself is not a disease, it is usually a marker for disease involving the heart.[3] Disease processes that can cause LVH include any disease that increases the afterload that the heart has to contract against, and some primary diseases of the muscle of the heart.[citation needed] Causes of increased afterload that can cause LVH include aortic stenosis, aortic insufficiency and hypertension. Primary disease of the muscle of the heart that cause LVH are known as hypertrophic cardiomyopathies, which can lead into heart failure.[citation needed]

Long-standing mitral insufficiency also leads to LVH as a compensatory mechanism.[citation needed]

LV mass increases with ageing.[4]

Associated genes include OGN (osteoglycin).[5]

Diagnosis

[edit]

The commonly used method to diagnose LVH is echocardiography, with which the thickness of the muscle of the heart can be measured. The electrocardiogram (ECG) often shows signs of increased voltage from the heart in individuals with LVH, so this is often used as a screening test to determine who should undergo further testing.[citation needed]

Echocardiography

[edit]
Left ventricular hypertrophy grading
by posterior wall thickness[6]
Mild 12 to 13 mm
Moderate >13 to 17 mm
Severe >17 mm

Two dimensional echocardiography can produce images of the left ventricle. The thickness of the left ventricle as visualized on echocardiography correlates with its actual mass. Left ventricular mass can be further estimated based on geometric assumptions of ventricular shape using the measured wall thickness and internal diameter.[7] Average thickness of the left ventricle, with numbers given as 95% prediction interval for the short axis images at the mid-cavity level are:[8]

  • Women: 4 – 8 mm
  • Men: 5 – 9 mm

CT & MRI

[edit]

CT and MRI-based measurement can be used to measure the left ventricle in three dimensions and calculate left ventricular mass directly. MRI based measurement is considered the "gold standard" for left ventricular mass,[9] though is usually not readily available for common practice. In older individuals, age related remodeling of the left ventricle's geometry can lead to a discordancy between CT and echocardiographic based measurements of left ventricular mass.[4]

ECG criteria

[edit]
Left ventricular hypertrophy with secondary repolarization abnormalities as seen on ECG
Histopathology of (a) normal myocardium and (b) myocardial hypertrophy. Scale bar indicates 50 μm.
Gross pathology of left ventricular hypertrophy. Left ventricle is at right in image, serially sectioned from apex to near base.

There are several sets of criteria used to diagnose LVH via electrocardiography.[10] None of them are perfect, though by using multiple criteria sets, the sensitivity and specificity are increased.

The Sokolow-Lyon index:[11][12]

  • S in V1 + R in V5 or V6 (whichever is larger) ≥ 35 mm (≥ 7 large squares)
  • R in aVL ≥ 11 mm

The Cornell voltage criteria[13] for the ECG diagnosis of LVH involve measurement of the sum of the R wave in lead aVL and the S wave in lead V3. The Cornell criteria for LVH are:

  • S in V3 + R in aVL > 28 mm (men)
  • S in V3 + R in aVL > 20 mm (women)

The Romhilt-Estes point score system ("diagnostic" >5 points; "probable" 4 points):

ECG Criteria Points
Voltage Criteria (any of):
  1. R or S in limb leads ≥20 mm
  2. S in V1 or V2 ≥30 mm
  3. R in V5 or V6 ≥30 mm
 3
ST-T Abnormalities:
  • ST-T vector opposite to QRS without digitalis
  • ST-T vector opposite to QRS with digitalis

3
1

Negative terminal P mode in V1 1 mm in depth and 0.04 sec in duration (indicates left atrial enlargement) 3
Left axis deviation (QRS of −30° or more) 2
QRS duration ≥0.09 sec 1
Delayed intrinsicoid deflection in V5 or V6 (>0.05 sec) 1

Other voltage-based criteria for LVH include:

  • Lead I: R wave > 14 mm
  • Lead aVR: S wave > 15 mm
  • Lead aVL: R wave > 12 mm
  • Lead aVF: R wave > 21 mm
  • Lead V5: R wave > 26 mm
  • Lead V6: R wave > 20 mm

Diagnostic accuracy of electrocardiography in left ventricular hypertrophy can be enhanced with artificial intelligence analysis.[14]

Treatment

[edit]

Treatment is typically focused on resolving the cause of the LVH with the enlargement not permanent in all cases. In some cases the growth can regress with the reduction of blood pressure.[15]

LVH may be a factor in determining treatment or diagnosis for other conditions, for example, LVH is used in the staging and risk stratification of Non-ischemic cardiomyopathies such as Fabry's Disease.[16] Patients with LVH may have to participate in more complicated and precise diagnostic procedures, such as echocardiography or cardiac MRI.[17][18]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Left ventricular hypertrophy

View on Grokipedia
from Grokipedia
Left ventricular hypertrophy (LVH) is a cardiac condition defined by the thickening of the walls of the left ventricle, the heart's main pumping chamber, which can result from increased workload on the heart and lead to impaired pumping efficiency and potential heart failure. This hypertrophy typically develops as a compensatory mechanism to hemodynamic stress, such as pressure overload from chronic hypertension or aortic stenosis, or volume overload from conditions like valvular regurgitation. The most common cause is uncontrolled high blood pressure, which forces the left ventricle to work harder, leading to gradual wall thickening and increased muscle mass. Other etiologies include genetic disorders like hypertrophic cardiomyopathy, infiltrative diseases such as amyloidosis, intense athletic training (resulting in physiological rather than pathological hypertrophy, in which a lower resting heart rate often coexists due to training adaptations, although the LVH itself does not cause bradycardia or low resting heart rate), and structural issues like coarctation of the aorta. LVH is often asymptomatic in its early stages, but as it progresses, individuals may experience during activity or at rest, , , , , or swelling in the legs and ankles due to fluid retention. Risk factors that contribute to its development include advancing age, , , female sex, and a family history of cardiac conditions. Untreated pathological LVH significantly elevates the risk of serious complications, including , arrhythmias such as , ischemic heart disease, , and sudden cardiac death, but is not associated with bradycardia or low resting heart rate. Diagnosis commonly involves (ECG), , or cardiac MRI to measure ventricular wall thickness and mass, while treatment focuses on addressing underlying causes through lifestyle modifications, medications like antihypertensives, or procedures such as .

Overview and Epidemiology

Definition and Classification

Left ventricular hypertrophy (LVH) is defined as an abnormal thickening of the myocardial wall of the left ventricle, the heart's main pumping chamber, resulting from chronic increased workload as an adaptive response to maintain . This condition is typically identified when the interventricular septal or posterior wall thickness exceeds 11 mm in adults, as measured by in . LVH is quantified not only by wall thickness but also by left ventricular mass index (LVMI), calculated as left ventricular mass divided by , with diagnostic thresholds generally set at greater than 95 g/m² in women and greater than 115 g/m² in men. LVH is classified into distinct morphological types based on patterns of remodeling and underlying hemodynamic stressors. Concentric LVH features increased wall thickness with a normal or reduced left ventricular chamber size, primarily arising from pressure overload conditions that promote parallel addition of s. In contrast, eccentric LVH involves increased left ventricular mass accompanied by chamber dilation, typically due to that leads to serial sarcomere addition. A separate category, physiological LVH, occurs in response to intense physical training, as seen in athlete's heart, and is characterized by mild, balanced that is reversible upon . In physiological LVH, a lower resting heart rate (bradycardia) commonly coexists with the hypertrophy due to training adaptations such as enhanced parasympathetic activity and increased stroke volume, but LVH itself does not cause the bradycardia. Assessment of LVH involves indexing left ventricular mass to to account for body size variations, ensuring accurate across diverse populations. Normal LVMI values exhibit differences by age, , and ; for instance, thresholds may be adjusted higher in individuals of African descent due to naturally greater baseline mass, with mean values around 70 g/m² in men and 61 g/m² in women in general populations, increasing modestly with age. Hypertension serves as a prevalent trigger for pathological LVH forms. Pathological LVH is not associated with bradycardia or low resting heart rate; some studies suggest that elevated resting heart rate may be linked to a higher risk of developing LVH or abnormal left ventricular geometry, particularly in hypertensive individuals. The recognition of LVH dates back to 19th-century autopsy studies that identified myocardial thickening in cases of chronic disease, such as , through gross pathological examination. Its formalization in modern occurred in the post-1970s era with the widespread adoption of noninvasive imaging modalities like , enabling precise measurement and classification.

Prevalence and Demographics

Left ventricular hypertrophy (LVH) affects approximately 15-20% of the general adult population worldwide, with prevalence estimates derived from large cohort studies such as the , where echocardiographic LVH was observed in 16% of men and 19% of women. In individuals with , the condition is substantially more common, occurring in 30-40% of cases according to echocardiographic assessments in meta-analyses of hypertensive cohorts. Recent population-based studies, including those from low- and middle-income countries, report similar or slightly higher rates, up to 39% in some community samples, underscoring its widespread occurrence across diverse settings. Demographic patterns reveal variations by , race/, and age. Prevalence is generally similar between men and women in the general population, though some studies indicate a slightly higher rate in women, particularly when indexed for body size, with ratios approaching 1.2:1 in older adults. Racial differences are pronounced, with exhibiting a 2- to 3-fold higher compared to Caucasians—approximately 25% versus 10%—attributable to a combination of genetic factors, such as variants influencing susceptibility, and socioeconomic influences on control. Age is a strong predictor, with roughly doubling after age 60; in the Framingham cohort, rates reached 33% in men and 49% in women over 65 years. Trends in LVH incidence are rising globally, driven by the obesity epidemic and increasing burdens, particularly in aging populations. , defined by a greater than 30, is associated with a 2-fold increased of developing LVH, independent of , as evidenced by longitudinal community studies linking adiposity to incident . Regional disparities are evident, with higher in low- and middle-income countries due to untreated and limited access to care; for instance, rates exceed 30% in some African and Asian cohorts compared to 10-15% in high-income settings with better control measures. Routine (ECG) screening detects only about 10% of LVH cases confirmed by , reflecting its low sensitivity (typically 7-20%) despite high specificity, which contributes to underdiagnosis in individuals. This limitation highlights the need for advanced imaging in high-risk groups, such as those with or , to improve early identification and intervention.

Pathophysiology

Hemodynamic Mechanisms

Left ventricular hypertrophy (LVH) primarily arises from hemodynamic stressors that impose chronic overload on the myocardium, prompting adaptive structural remodeling to maintain . In pressure overload, such as that seen in chronic hypertension with systolic exceeding 140 mmHg, the elevated increases systolic wall stress, stimulating cardiomyocytes to add sarcomeres in parallel. This thickens the ventricular wall, thereby reducing wall stress according to , which describes myocardial wall tension as σ=P×r2h\sigma = \frac{P \times r}{2h}, where σ\sigma is wall stress, PP is intraventricular , rr is ventricular radius, and hh is wall thickness. In contrast, , often from conditions like aortic or , elevates preload and diastolic filling, leading to eccentric through the addition of sarcomeres in series within cardiomyocytes. This process elongates and dilates the ventricular chamber to accommodate the increased while attempting to normalize diastolic wall stress. The distinction between these patterns underscores the ventricle's biomechanical response to specific loading conditions, with pressure overload favoring wall thickening and promoting chamber enlargement. Initially, this hypertrophic response is adaptive, compensating for overload by restoring wall stress toward normal levels and preserving ; however, prolonged stress shifts it to maladaptive , characterized by interstitial , impaired relaxation, and eventual contractile dysfunction. The transition to heart occurs when can no longer adequately normalize stress, resulting in progressive ventricular dilation and systolic impairment. Clinically, left ventricular mass is quantified echocardiographically using the American Society of Echocardiography (ASE) formula: LV mass (g)=0.8{1.04[(IVSd+PWd+LVIDd)3−LVIDd3]}+0.6\text{LV mass (g)} = 0.8 \left\{ 1.04 \left[ (\text{IVSd} + \text{PWd} + \text{LVIDd})^3 - \text{LVIDd}^3 \right] \right\} + 0.6 where IVSd is interventricular septal thickness at end-diastole (cm), PWd is posterior wall thickness at end-diastole (cm), and LVIDd is left ventricular internal diameter at end-diastole (cm), providing a standardized measure of hypertrophic progression.

Cellular and Molecular Processes

Left ventricular hypertrophy (LVH) involves the activation of multiple intracellular signaling pathways that promote cardiomyocyte enlargement and contribute to pathological remodeling. The calcineurin-NFAT pathway plays a central role in pathological hypertrophy, where increased intracellular calcium activates calcineurin, leading to dephosphorylation and nuclear translocation of NFAT transcription factors, which drive hypertrophic gene programs. Similarly, the MAPK/ERK pathway is activated by mechanical stress and growth factors, phosphorylating transcription factors that induce myocyte hypertrophy and fibrosis. The PI3K-Akt pathway, often triggered by insulin-like growth factors, promotes protein synthesis and cell survival but can exacerbate hypertrophy when dysregulated. Angiotensin II, acting through AT1 receptors on cardiomyocytes, further amplifies these signals by stimulating G-protein-coupled pathways that enhance calcineurin and MAPK activation, leading to concentric hypertrophy. At the transcriptional level, LVH is characterized by a fetal gene program reactivation, indicating maladaptive remodeling. Upregulation of (ANP) and (BNP) occurs early in hypertrophy, serving as biomarkers of stress and contributing to through autocrine effects. The switch from adult α-myosin heavy chain (α-MHC) to fetal β-myosin heavy chain (β-MHC) reduces contractile efficiency and energy utilization, promoting progression to heart failure. Concurrently, downregulation of sarco/endoplasmic reticulum Ca²⁺-ATPase 2a (SERCA2a) impairs calcium reuptake into the sarcoplasmic reticulum, resulting in diastolic dysfunction and slowed relaxation. Extracellular matrix (ECM) remodeling in LVH involves fibroblast activation and excessive collagen deposition, which increases myocardial stiffness and impairs diastolic function. Cardiac fibroblasts proliferate and differentiate into myofibroblasts, synthesizing types I and III collagen in response to mechanical stretch and humoral factors. The transforming growth factor-β (TGF-β) pathway is pivotal, as TGF-β1 upregulates collagen genes via Smad signaling, promoting fibrosis and perivascular collagen accumulation. This imbalance between matrix metalloproteinases and tissue inhibitors of metalloproteinases further sustains ECM accumulation, transitioning hypertrophy from compensated to decompensated states. Epigenetic modifications modulate LVH progression by altering gene accessibility without changing DNA sequence. MicroRNAs, such as miR-21, are upregulated in hypertrophied cardiomyocytes and fibroblasts, targeting PTEN to activate PI3K-Akt signaling and enhance hypertrophy while promoting fibrosis. Histone modifications, including acetylation and methylation, influence chromatin structure; for instance, histone deacetylase inhibition can repress fetal gene expression. Sex differences arise partly through estrogen-mediated protection in females, where estrogen receptors suppress pro-hypertrophic miRNAs and pathways, reducing fibrosis and hypertrophy compared to males.

Etiology

Pressure Overload Causes

Pressure overload on the left ventricle, primarily through increased afterload, leads to concentric hypertrophy as a compensatory mechanism to normalize wall stress, as described in hemodynamic principles of cardiac adaptation. Hypertension represents the predominant etiology of pressure overload-induced left ventricular hypertrophy (LVH), accounting for the majority of cases worldwide. Essential hypertension, characterized by sustained elevation in systemic blood pressure without identifiable secondary causes, drives LVH through chronic exposure to elevated afterload, with prevalence estimates indicating it underlies 70-80% of LVH in hypertensive populations. In elderly individuals, isolated systolic hypertension—defined as systolic blood pressure ≥140 mmHg with diastolic <90 mmHg—predominates due to age-related arterial stiffening and is strongly associated with concentric LVH, increasing left ventricular wall thickness even in borderline cases. Secondary forms of hypertension, such as that arising from renal artery stenosis, contribute to LVH by activating the renin-angiotensin-aldosterone system, leading to renovascular pressure overload; this condition accounts for 10-45% of secondary hypertension cases and is a correctable cause of LVH progression. Aortic valve disorders impose significant pressure overload via obstruction to left ventricular outflow. Aortic stenosis, the most common valvular cause, results in LVH as the ventricle compensates for transvalvular pressure gradients; it affects approximately 2-3% of individuals over age 65, with prevalence rising to 7% beyond age 80. Bicuspid aortic valve, a congenital anomaly present in 1-2% of the population, predisposes to early calcific stenosis and associated LVH, comprising about 50% of surgical aortic stenosis cases in adults under 70. Calcific aortic stenosis, the degenerative form prevalent in the elderly, leads to progressive valve narrowing and myocardial hypertrophy through fibro-calcific remodeling, often culminating in severe obstruction and symptomatic LVH. Coarctation of the aorta, a congenital narrowing typically distal to the left subclavian artery, generates upper body hypertension and LVH; its incidence is 0.3-0.4 per 1000 live births, and even post-repair, persistent hypertension sustains LVH in up to 50% of adults. The athlete's paradox highlights the challenge in distinguishing physiological from pathological LVH under pressure overload conditions. Endurance training induces eccentric LVH with cavity dilation and modest wall thickening to accommodate increased stroke volume, whereas resistance training promotes concentric LVH resembling pathological patterns through repetitive afterload elevation; wall thickness exceeding 13 mm in athletes warrants evaluation to rule out underlying HCM or hypertensive etiology. Physiological adaptations in athletes are typically reversible with detraining, contrasting with the progressive fibrosis and dysfunction in pathological pressure overload LVH.

Volume Overload and Other Causes

Volume overload contributes to eccentric left ventricular hypertrophy (LVH), characterized by chamber dilatation and proportional wall thickening in response to increased preload, distinguishing it from the concentric remodeling seen in pressure overload states. This pattern arises when the left ventricle accommodates excess blood volume, leading to sarcomere addition in series and overall myocardial expansion. Valvular regurgitations are primary causes of chronic volume overload. In aortic regurgitation, blood refluxes from the aorta into the left ventricle during diastole, imposing a substantial preload burden that triggers eccentric , particularly in chronic cases following endocarditis or degenerative valve disease. Acute aortic regurgitation, such as from infective endocarditis rupture, can rapidly escalate volume overload, though the hypertrophic response may lag behind initial decompensation. Similarly, mitral regurgitation, whether due to myxomatous degeneration or ischemic papillary muscle dysfunction, directs blood back into the left atrium and ventricle, increasing end-diastolic volume and promoting eccentric hypertrophy to maintain forward stroke volume. High-output states further drive volume overload by elevating cardiac preload through increased circulating volume or flow rates. Chronic anemia, typically with hemoglobin levels below 10 g/dL, stimulates compensatory tachycardia and augmented stroke volume, resulting in eccentric as the ventricle adapts to the heightened oxygen demand. Thyrotoxicosis, most commonly from , induces a hypermetabolic state with elevated cardiac output, leading to left ventricular dilatation and hypertrophy that often reverses with treatment of the underlying hyperthyroidism. Arteriovenous fistulas, such as those created for hemodialysis access, shunt blood directly from arteries to veins, increasing venous return and preload, which fosters eccentric ; closure of large fistulas has been shown to regress this hypertrophy over time. Certain cardiomyopathies manifest as causes of eccentric LVH. Dilated cardiomyopathy, whether idiopathic or post-viral, features progressive left ventricular enlargement with systolic dysfunction, where initial eccentric hypertrophy compensates for the increased wall stress from chamber dilation. Hypertrophic cardiomyopathy (HCM) is a genetic cause of LVH, where sarcomere dysfunction impairs myocardial relaxation and contractility, promoting asymmetric LVH independent of afterload in many cases but often overlapping with obstructive physiology. Mutations in sarcomere protein genes are identified in 50-60% of familial HCM cases, with the MYH7 gene encoding β-myosin heavy chain being among the most common, accounting for 20-30% of mutations and associated with severe hypertrophy and outflow obstruction. HCM manifests in obstructive (approximately 30% of cases, with left ventricular outflow tract gradients >30 mmHg) and non-obstructive forms, both leading to concentric or asymmetric LVH as a primary pathological rather than secondary response. Infiltrative cardiomyopathies like involve extracellular deposition of amyloid proteins, leading to restrictive physiology and concentric LVH patterns; light-chain ( stems from , while transthyretin (ATTR) types—wild-type or variant—predominate in older adults, with prevalence approaching 1% in those over 60 years and higher rates (up to 13-19%) among elderly patients with unexplained LVH. Other non-hemodynamic factors contribute to eccentric LVH through indirect mechanisms. promotes LVH via neurohormonal activation, including overstimulation and renin-angiotensin-aldosterone system upregulation, which increase preload and while fostering adipose-derived inflammatory signals that drive myocardial remodeling. In , uremic arises from uremia-induced , electrolyte imbalances, and fluid retention, culminating in eccentric LVH as a hallmark feature that correlates with disease progression and cardiovascular mortality.

Clinical Manifestations

Symptoms and Signs

Left ventricular hypertrophy (LVH) often manifests with cardiac symptoms related to impaired ventricular filling and increased myocardial oxygen demand, particularly in advanced cases driven by underlying conditions such as . Patients commonly experience dyspnea on exertion, typically corresponding to New York Heart Association (NYHA) functional class II or III, due to diastolic dysfunction limiting during physical activity. pectoris may occur secondary to subendocardial ischemia, as the thickened myocardium outstrips coronary blood supply, especially during exertion. are frequent, arising from arrhythmias such as or ventricular ectopy, which are promoted by the altered electrophysiological substrate in hypertrophied tissue. In decompensated states, LVH can lead to overt signs characterized by fluid overload and pulmonary congestion. results from elevated left atrial pressure redistributing fluid to the lungs in the , while paroxysmal nocturnal dyspnea involves sudden awakenings with severe due to acute . , often in the lower extremities, reflects right-sided involvement or biventricular failure in progressive disease. Physical examination reveals key auscultatory and palpatory findings indicative of ventricular stiffness and pressure overload. An S4 gallop is commonly audible, representing atrial contraction against a noncompliant left ventricle during late . The apical impulse is typically sustained and displaced laterally or inferiorly, reflecting the enlarged left ventricular mass. In cases associated with systemic hypertension, a loud second heart sound (S2) may be present due to accentuated closure from elevated pressures. For LVH secondary to , a bisferiens carotid —characterized by a double peak—can be palpated, stemming from the combined effects of obstruction and regurgitation if mixed valvular disease is present. Associated features include generalized fatigue from reduced cardiac reserve and syncope, particularly in variants with dynamic outflow tract obstruction, where exertion provokes transient . These manifestations underscore the need for prompt evaluation when symptoms emerge in the context of predisposing factors like uncontrolled .

Asymptomatic Presentations

Left ventricular hypertrophy (LVH) is frequently detected incidentally in asymptomatic individuals through routine screening modalities, such as (ECG) during annual health checkups or hypertension management, where criteria like the Sokolow-Lyon index (S wave in V1 plus R wave in V5 or V6 exceeding 35 mm) identify potential cases in approximately 10-15% of screened populations. Pre-operative , often performed prior to non-cardiac surgeries in older adults or those with risk factors, can reveal LVH in cases without prior clinical suspicion. In athletic populations, routine cardiac evaluations using or cardiac magnetic resonance imaging may uncover mild hypertrophy as part of physiological adaptations, prompting differentiation from pathological forms. The prevalence of silent LVH varies by but is notably high among those with untreated or poorly controlled , reaching up to 44% in asymptomatic primary care patients aged 60-85 years with long-standing disease, and escalating to 60% in those aged 75 years and older. In the general , asymptomatic LVH occurs in 15-20% of individuals, with higher rates in the elderly due to cumulative hemodynamic stress. These findings underscore the value of targeted screening in at-risk groups, such as hypertensives and the elderly, to identify silent LVH before progression to symptomatic . Even in the absence of symptoms, LVH carries significant prognostic weight, conferring a 2- to 4-fold increased of sudden cardiac compared to those without , independent of other cardiovascular factors. Early interventions, including control and lifestyle modifications, can promote regression of LVH, thereby mitigating this elevated and improving long-term cardiovascular outcomes. This highlights the importance of incidental detection for timely management to prevent adverse events. A key challenge in interpreting asymptomatic LVH lies in distinguishing pathological from physiological , particularly in athletes, where left ventricular wall thickness below 13 is typically benign and reversible with detraining, whereas thicknesses at or above this threshold warrant further evaluation for underlying pathology.

Electrocardiographic Criteria

Electrocardiography () is a widely available, non-invasive initial screening tool for left ventricular hypertrophy (LVH), primarily relying on voltage measurements and patterns to detect increased left ventricular mass electrically. Although ECG criteria are standardized and validated, they exhibit low overall sensitivity (typically 20% to 50%) but high specificity (85% to 95%), making them useful for ruling in LVH when positive but less reliable for excluding it. The ()/ () guidelines endorse ECG as part of the initial evaluation in patients with risk factors such as , recommending it to identify voltage abnormalities, arrhythmias, or changes suggestive of LVH, though it is not considered diagnostic in isolation and should prompt confirmatory imaging. Voltage-based criteria form the cornerstone of ECG diagnosis for LVH, focusing on increased amplitudes in precordial and limb leads due to the enlarged myocardial mass. The Sokolow-Lyon criterion, a seminal method developed in 1949, identifies LVH when the sum of the depth in V1 (SV1) plus the wave height in V5 or V6 (RV5 or RV6) exceeds 35 mm; it offers moderate sensitivity around 45% but high specificity near 90%, particularly in non-obese populations.90162-1) The Cornell criterion, refined for gender differences, defines LVH as SV3 plus the wave in aVL (RaVL) greater than 28 mm in men or 20 mm in women, achieving similar sensitivity (<50%) and specificity (85% to 90%), with improved performance when combined with QRS duration to form a voltage-duration product.80252-5) For broader assessment, the Romhilt-Estes point-score system integrates multiple features (e.g., voltage, ST-T changes, left atrial involvement), assigning points where a score greater than 4 indicates probable LVH and 5 or more suggests definite LVH; this multiparametric approach enhances risk stratification for cardiovascular events beyond simple voltage alone.90098-1) Beyond voltage, ECG patterns such as repolarization abnormalities and atrial changes provide supportive evidence of LVH. The classic "strain" pattern, observed in up to 30% of LVH cases, manifests as downsloping ST-segment depression and asymmetric T-wave inversion in the lateral leads (I, aVL, V5, and V6), reflecting subendocardial ischemia from hypertrophy; this pattern independently predicts adverse outcomes like heart failure and mortality. Accompanying left atrial enlargement, often due to elevated left ventricular filling pressures, appears as P mitrale—a broad, notched P wave (>120 ms) in lead II with a deep negative terminal deflection (>1 mm deep and >40 ms wide) in V1—further supporting the diagnosis in chronic pressure-overload states. Despite its utility, ECG criteria for LVH have notable limitations that reduce clinical reliability in certain groups. Sensitivity drops to 20% or lower in obese individuals, where increased thoracic impedance attenuates QRS voltages, leading to underdiagnosis despite higher LVH prevalence in this population. Conversely, false positives occur frequently in young adults and athletes, where physiologic from a thin chest wall or physiologic adaptation mimics LVH, potentially resulting in unnecessary testing. The Romhilt-Estes score, while aiding risk stratification (e.g., scores >4 correlate with increased cardiovascular mortality), shares these sensitivity issues and is best used adjunctively rather than as a sole determinant.90098-1) Overall, these constraints underscore ECG's role as a screening adjunct, with remaining the gold standard for anatomic confirmation.
CriterionDescriptionSensitivitySpecificitySource
Sokolow-LyonSV1 + RV5/V6 > 35 mm~45%~90%
CornellSV3 + RaVL >28 mm (men), >20 mm (women)<50%85-90%
Romhilt-EstesScore >4 points (probable LVH); ≥5 (definite)30-50%80-90%90098-1)

Echocardiographic Assessment

Echocardiography serves as the primary non-invasive imaging modality for diagnosing and quantifying left ventricular hypertrophy (LVH), providing direct visualization of cardiac structures and function. Two-dimensional (2D) echocardiography, particularly in the parasternal long-axis view, is used to measure left ventricular wall thickness, including the and posterior wall at end-diastole. These measurements are taken from inner edge to inner edge, perpendicular to the beam, to assess , with wall thickness exceeding 11 mm in women or 12 mm in men indicating LVH. complements structural evaluation by assessing hemodynamic gradients, such as in , where a peak transvalvular velocity greater than 4 m/s signifies severe contributing to overload and LVH. Quantification of LV mass relies on standardized formulas recommended by the American Society of (ASE) and European Association of (EAE). The ASE/EAE formula for LV mass from linear dimensions is LV mass = 0.8 × 1.04 × [(IVSd + LVIDd + PWd)^3 – (LVIDd)^3] + 0.6 g, where IVSd is interventricular septal thickness at end-diastole, LVIDd is left ventricular internal diameter at end-diastole, and PWd is posterior wall thickness at end-diastole; this is indexed to for clinical interpretation, with values exceeding 95 g/m² in women or 115 g/m² in men diagnostic of LVH. Relative wall thickness (RWT), calculated as RWT = 2 × PWd / LVIDd, helps classify LV geometry; an RWT greater than 0.42 indicates , distinguishing it from eccentric patterns seen in . Functional assessment via evaluates both systolic and diastolic performance in LVH. Ejection fraction, typically preserved above 50% in early LVH, is calculated using the Simpson biplane method from apical views, reflecting adequate systolic function despite hypertrophy. Diastolic parameters, including the mitral inflow derived from pulsed-wave Doppler, often show impairment with an less than 1, indicating delayed relaxation as an early marker of diastolic dysfunction in LVH. The advantages of echocardiography include its non-invasive nature, portability, lack of , and ability to provide real-time imaging for immediate clinical decision-making. It excels in serial monitoring, enabling detection of LVH regression; for instance, antihypertensive can achieve 10-20% reduction in LV mass over 1-2 years, correlating with improved .

Advanced Imaging Techniques

Advanced imaging techniques, such as cardiac computed tomography (CT) and magnetic resonance imaging (), provide detailed characterization of left ventricular hypertrophy (LVH) in scenarios where echocardiography yields inconclusive results or when tissue-level assessment is required. These modalities are particularly valuable for evaluating myocardial , infiltrative processes, and viability in ischemic contexts, complementing the structural focus of echocardiography as the primary diagnostic tool. Cardiac CT, often performed via multidetector systems, enables precise quantification of left ventricular mass with high accuracy compared to , showing strong correlations and minimal bias against cardiac MRI as the reference standard. Coronary calcium (CAC) scoring using the Agatston method on noncontrast CT scans identifies high-risk LVH phenotypes, with elevated scores associated with adverse remodeling and increased cardiovascular events independent of traditional risk factors. For instance, CAC scores greater than 100 indicate intermediate risk and correlate with LVH progression in population-based cohorts. Cardiac MRI serves as the gold standard for myocardial tissue characterization in LVH, offering superior resolution for detecting focal and diffuse abnormalities. Late gadolinium enhancement (LGE) imaging identifies replacement , appearing as mid-wall or subendocardial patterns in hypertensive or ischemic LVH, respectively. T1 mapping quantifies diffuse , with elevated native T1 relaxation times exceeding 1200 ms signaling early fibrotic changes in conditions like or . Indications for these advanced techniques include discrepancies between echocardiographic wall thickness and electrocardiographic voltage criteria, prompting evaluation for infiltrative etiologies. In suspected , cardiac MRI reveals characteristic global subendocardial LGE and elevated extracellular volume, aiding differentiation from other causes of LVH. Additionally, MRI assesses myocardial viability in ischemic LVH through LGE patterns and perfusion imaging. Despite their utility, limitations include high costs and limited availability for both CT and MRI, restricting routine use. Cardiac CT involves exposure of approximately 5 mSv for calcium scoring protocols, while MRI is contraindicated in patients with non-MRI-conditional pacemakers or severe . Emerging applications in the 2020s enhance automated quantification of ventricular mass and on both modalities, improving reproducibility and efficiency in clinical practice.

Management

Lifestyle and Non-Pharmacological Interventions

Lifestyle modifications form the cornerstone of managing left ventricular hypertrophy (LVH), particularly when driven by underlying conditions such as , by addressing modifiable risk factors to promote regression of ventricular mass and improve cardiac function. The , emphasizing reduced sodium intake to less than 2.3 grams per day and increased consumption of potassium-rich foods like fruits and , has been shown to lower and enhance diastolic function in patients with hypertensive with preserved . supplementation in this context can ameliorate cardiac by mitigating imbalances that exacerbate myocardial remodeling. Regular , targeting at least 150 minutes per week of moderate-intensity activity such as brisk walking or , supports LVH regression by reducing and improving . In randomized trials, 16 weeks of structured aerobic training led to substantial decreases in left ventricular mass and wall thickness among patients with hypertension-related LVH. Intensive interventions incorporating diet and exercise have also demonstrated regression of electrocardiographic LVH in individuals with cardiovascular risk factors. Weight management is critical, with a target below 25 kg/m² recommended to alleviate hemodynamic stress on the left ventricle. In cases of severe , such as Roux-en-Y gastric bypass can significantly reduce left ventricular mass by normalizing aortic function and promoting reverse remodeling. is essential, as tobacco use promotes that contributes to and progression of LVH; quitting reduces these effects and lowers in hypertensive individuals at risk for . Home blood pressure monitoring facilitates ongoing management by enabling patients to track readings and achieve tighter control, which is associated with slower progression of LVH. For patients with LVH complicating , cardiac resynchronization therapy (CRT) via device implantation improves left ventricular synchrony and symptoms, with approximately 60% experiencing enhancement in New York Heart Association functional class.

Pharmacological Treatments

Pharmacological treatments for left ventricular hypertrophy (LVH) primarily target the underlying etiology, such as or (HCM), with the goal of regressing myocardial mass, reducing wall stress, and preventing progression to heart failure. These therapies, particularly antihypertensives, have demonstrated efficacy in reversing LVH through control and direct effects on cardiac remodeling. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are cornerstone therapies for hypertensive LVH due to their blockade of the renin-angiotensin-aldosterone system (RAAS), which reduces afterload, inhibits myocyte hypertrophy, and promotes regression of left ventricular mass by 10-13%. Examples include lisinopril at doses of 20-40 mg daily, which has shown significant LV mass reduction in clinical trials, and losartan, which outperforms other classes in meta-analyses for LVH reversal. A meta-analysis confirmed that ACE inhibitors and ARBs achieve regression of up to 12.5% in LV mass index with ARBs. Beta-blockers, such as metoprolol at 50-200 mg daily, mitigate LVH by lowering heart rate and myocardial oxygen demand, thereby decreasing wall stress, though they induce less regression (approximately 6-10%) than RAAS inhibitors. These agents are particularly useful in HCM to control symptoms and outflow tract gradients. For obstructive HCM, cardiac myosin inhibitors such as mavacamten (starting dose 5 mg daily, titrated based on echocardiographic and LVEF monitoring) are recommended to reduce left ventricular outflow tract obstruction and promote LV remodeling, as per 2024 guidelines. Calcium channel blockers (CCBs) are selected based on subtype and ; non-dihydropyridine CCBs like verapamil (120-480 mg daily) are recommended for HCM to improve diastolic filling and reduce hypertrophy-related symptoms, while dihydropyridine CCBs such as amlodipine (5-10 mg daily) aid regression in hypertensive LVH by vasodilating and reducing , achieving about 11% LV mass decrease. Meta-analyses indicate CCBs are comparable to ACE inhibitors in efficacy but may be preferred in patients with comorbid arrhythmias. Diuretics play a supportive role in volume overload contributing to LVH; thiazides like hydrochlorothiazide (12.5-25 mg daily) control fluid retention and , leading to modest LV mass regression of around 8%. antagonists, such as at 25 mg daily, offer additional antifibrotic benefits by inhibiting aldosterone-mediated deposition, with 2020s trials like the study showing reduced LV mass and fibrosis progression in patients with and . Treatment is tailored to the LVH etiology; for instance, statins like (10-80 mg daily) are incorporated in ischemic LVH to attenuate remodeling and improve outcomes beyond lipid lowering, as evidenced by experimental and clinical data. A meta-analysis highlights ARBs as achieving greater regression in hypertensive patients, emphasizing as an adjunct to interventions for optimal results.

Surgical and Device-Based Therapies

Surgical interventions for left ventricular hypertrophy (LVH) are indicated in cases of severe, drug-refractory disease driven by specific etiologies, such as or (HCM), to address the underlying structural abnormalities and promote reverse remodeling. These procedures aim to alleviate pressure or , reducing ventricular wall stress and facilitating hypertrophy regression. In patients with , a common cause of pressure-overload LVH, —either surgical (SAVR) or transcatheter (TAVR)—relieves the obstruction and unloads the left ventricle. Post-procedure, left ventricular mass typically regresses by 20-30% within the first year, with greater reductions observed in cases of appropriate preoperative hypertrophy. Similarly, for leading to volume-overload LVH, is the preferred approach, as it corrects the regurgitant lesion and supports normalization of left ventricular morphology and function, particularly in the early postoperative period. For obstructive HCM, where dynamic left ventricular outflow tract (LVOT) obstruction contributes to hypertrophy and symptoms, septal myectomy remains the gold-standard invasive therapy. This open-heart procedure involves surgical excision of the hypertrophied , reducing the resting LVOT gradient by more than 50 mmHg in most cases and achieving symptomatic improvement in over 90% of patients. As a less invasive alternative, alcohol septal ablation uses injection of alcohol into a septal perforator artery to induce targeted , yielding an approximately 80% success rate in gradient reduction and symptom relief. Device-based therapies complement surgical options in select high-risk scenarios. Implantable cardioverter-defibrillators (ICDs) are recommended for primary prevention of sudden cardiac death in HCM patients with massive hypertrophy (maximal wall thickness >30 mm) or other risk factors like family history of sudden death. In end-stage with decompensated LVH, left (LVAD) implantation provides mechanical circulatory support as a bridge to transplantation, enabling potential left ventricular unloading and remodeling in patients with restrictive or hypertrophic phenotypes. Perioperative risks for aortic valve replacement include mortality rates of 1-5%, influenced by patient comorbidities and procedural complexity. Long-term echocardiographic monitoring is crucial to evaluate LV remodeling, hypertrophy regression, and functional outcomes following these interventions.

Prognosis and Prevention

Long-Term Outcomes and Complications

Left ventricular hypertrophy (LVH) is associated with a substantially elevated risk of cardiovascular events, with untreated patients facing a 5-year major adverse cardiovascular event (MACE) rate of approximately 20-30%, depending on severity and underlying etiology. For instance, in cohorts with moderate to severe LVH due to Fabry disease, 5-year MACE rates have been reported as high as 30.5%. Regression of LVH through targeted therapy can significantly mitigate this risk; in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial, losartan-based antihypertensive therapy led to greater LVH regression compared to atenolol and was associated with a 25% relative reduction in the composite endpoint of cardiovascular death, stroke, and myocardial infarction versus atenolol, effectively halving the excess risk attributable to persistent LVH. Complications of LVH include a heightened propensity for arrhythmias, particularly (AFib), which occurs in 20-25% of patients, especially those with (HCM)-related LVH. Pathological LVH is not associated with bradycardia or low resting heart rate. Sudden cardiac death (SCD) risk is notably elevated in HCM, at approximately 0.2% per year, driven by ventricular arrhythmias and . In broader LVH populations, such as those with , the annual SCD incidence is approximately 0.3%, often linked to ischemic or arrhythmic triggers. Additionally, LVH predisposes to heart failure with preserved ejection fraction (HFpEF) through progressive diastolic dysfunction and increased myocardial stiffness, with up to 50% of HFpEF cases featuring concomitant LVH as a transitional pathology. Reversibility of LVH varies with intervention timing and intensity, but reductions in left ventricular mass of 10-25% are achievable with stringent control targeting less than 130/80 mmHg, particularly using renin-angiotensin system inhibitors. However, irreversible myocardial , detectable via cardiac (MRI) as late enhancement, limits regression potential and independently predicts adverse outcomes, including higher rates of hospitalization and mortality. Overall mortality in LVH is increased approximately 2-fold compared to individuals without hypertrophy, reflecting compounded risks from coronary disease, arrhythmias, and . Ethnic disparities exacerbate this burden, with individuals exhibiting a higher prevalence and severity of LVH, contributing to elevated cardiovascular mortality; the Atherosclerosis Risk in Communities (ARIC) study demonstrated that LVH conferred a greater for cardiovascular events and death in participants versus Whites, underscoring socioeconomic and biologic factors in these outcomes.

Strategies for Prevention

Preventing left ventricular hypertrophy (LVH) primarily involves targeting modifiable risk factors through early screening, modifications, and initiatives to mitigate its development in at-risk populations. Risk factor control begins with early hypertension screening and management, as uncontrolled high is a leading cause of LVH. Guidelines recommend routine screening starting in early adulthood, with a treatment target of less than 130/80 mm Hg for adults to prevent cardiac remodeling. Intensive lowering to this threshold has been shown to reduce left ventricular mass and prevent progression to hypertrophy in hypertensive individuals. For , which independently promotes LVH through mechanisms like increased cardiac workload, childhood interventions focusing on —such as dietary counseling and increased —can decrease the prevalence of LVH in affected children by up to 14% and attenuate long-term adult cardiac structural changes. Public health strategies emphasize population-level interventions to address shared risk factors. Salt reduction campaigns, aligned with recommendations to limit intake to less than 5 g per day, effectively lower and reduce the incidence of hypertension-related LVH by promoting vascular and cardiac . In families with genetic predispositions like (HCM), a common heritable cause of LVH, cascade screening through identifies at-risk relatives, enabling early monitoring and preventive measures; programs have achieved up to 61% uptake for among relatives. Lifestyle promotion plays a central role, with regular recommended to counteract sedentary behaviors that contribute to LVH. Current guidelines advocate for at least 150 minutes of moderate-intensity per week, equivalent to approximately 7,000–10,000 steps daily, which lowers cardiovascular risk factors like and that drive . For , maintaining HbA1c below 7% in individuals with is crucial, as poor glycemic control elevates left ventricular mass and doubles the risk of hypertrophy compared to non-diabetic populations. As of 2025, emerging approaches include the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors for high-risk groups with to prevent cardiac remodeling. Trials like EMPA-REG OUTCOME demonstrated that empagliflozin reduces cardiovascular events and left ventricular mass in patients with .

References

  1. https://www.mayoclinic.org/diseases-conditions/left-ventricular-hypertrophy/symptoms-causes/syc-20374314
  2. https://www.ncbi.nlm.nih.gov/books/NBK557534/
  3. https://my.clevelandclinic.org/health/diseases/23920-athletes-heart
  4. https://www.sciencedirect.com/science/article/abs/pii/S0363018819302075
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC4958512/
  6. https://www.ahajournals.org/doi/10.1161/circimaging.109.883652
  7. https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.125.325638
  8. https://journals.physiology.org/doi/full/10.1152/physiol.00043.2010?doi=10.1152/physiol.00043.2010
  9. https://www.jacc.org/doi/10.1016/j.jcmg.2015.02.014
  10. https://www.sciencedirect.com/science/article/abs/pii/S0894731715007269
  11. https://pubmed.ncbi.nlm.nih.gov/11288805/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC8298245/
  13. https://www.sciencedirect.com/science/article/pii/S0735109721082735
  14. https://pubmed.ncbi.nlm.nih.gov/2962527/
  15. https://journals.lww.com/jhypertension/fulltext/2011/06001/prevalence_of_left_ventricular_hypertrophy_in.109.aspx
  16. https://www.nature.com/articles/s41598-025-96837-3
  17. https://www.ahajournals.org/doi/10.1161/01.hyp.0000169972.96201.8e
  18. https://www.ahajournals.org/doi/10.1161/01.HYP.25.2.242
  19. https://www.ahajournals.org/doi/10.1161/JAHA.123.033521
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC12043564/
  21. https://pubmed.ncbi.nlm.nih.gov/2137733/
  22. https://pubmed.ncbi.nlm.nih.gov/8370376/
  23. https://www.ahajournals.org/doi/10.1161/01.CIR.102.4.470
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC7031419/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC8538325/
  26. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2020.00092/full
  27. https://journals.physiology.org/doi/10.1152/japplphysiol.00834.2003
  28. https://www.asecho.org/wp-content/uploads/2016/02/2015_ChamberQuantificationREV.pdf
  29. https://www.mdpi.com/1422-0067/20/9/2164
  30. https://academic.oup.com/cardiovascres/article/63/3/403/344514
  31. https://www.pnas.org/doi/10.1073/pnas.0605545103
  32. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0092903
  33. https://www.pnas.org/doi/10.1073/pnas.97.2.793
  34. https://www.jacc.org/doi/10.1016/j.jacc.2006.04.004
  35. https://www.ahajournals.org/doi/10.1161/01.cir.96.11.4065
  36. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0078558
  37. https://www.nature.com/articles/s41392-022-01055-2
  38. https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.124.325447
  39. https://pubmed.ncbi.nlm.nih.gov/8131759/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC3132610/
  41. https://www.ncbi.nlm.nih.gov/books/NBK551587/
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC12059746/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC1804143/
  44. https://www.ncbi.nlm.nih.gov/books/NBK557628/
  45. https://pubmed.ncbi.nlm.nih.gov/22592728/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC2300466/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC1905938/
  48. https://pubmed.ncbi.nlm.nih.gov/12751134/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC7154424/
  50. https://www.ahajournals.org/doi/10.1161/circulationaha.107.755942
  51. https://www.ncbi.nlm.nih.gov/books/NBK553135/
  52. https://pubmed.ncbi.nlm.nih.gov/19136608/
  53. https://pubmed.ncbi.nlm.nih.gov/2525871/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC5512680/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC3623610/
  56. https://pubmed.ncbi.nlm.nih.gov/15575907/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC8375600/
  58. https://pubmed.ncbi.nlm.nih.gov/8874989/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC5654557/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC4349164/
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC8318443/
  62. https://pubmed.ncbi.nlm.nih.gov/31210553/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC4871748/
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC2827803/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC6066558/
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC4662296/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC9135932/
  68. https://www.heart.org/en/health-topics/heart-valve-problems-and-disease/heart-valve-problems-and-causes/what-is-left-ventricular-hypertrophy-lvh
  69. https://www.ncbi.nlm.nih.gov/books/NBK537098/
  70. https://www.ncbi.nlm.nih.gov/books/NBK345/
  71. https://www.mayoclinic.org/diseases-conditions/hypertrophic-cardiomyopathy/symptoms-causes/syc-20350198
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC7443300/
  73. https://www.ahajournals.org/doi/10.1161/01.hyp.29.5.1095
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC5303558/
  75. https://bmjopen.bmj.com/content/10/8/e038824
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC8673408/
  77. https://pubmed.ncbi.nlm.nih.gov/8213586/
  78. https://www.ahajournals.org/doi/10.1161/circulationaha.108.191097
  79. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000937
  80. https://www.ahajournals.org/doi/10.1161/hyp.0000000000000065
  81. https://www.ahajournals.org/doi/10.1161/01.CIR.63.6.1391
  82. https://www.ahajournals.org/doi/10.1161/01.hyp.0000132556.91792.6a
  83. https://ecgwaves.com/topic/ecg-left-ventricular-hypertrophy-lvh-clinical-characteristics/
  84. https://litfl.com/left-atrial-enlargement-ecg-library/
  85. https://www.ahajournals.org/doi/10.1161/01.HYP.35.1.13
  86. https://pubmed.ncbi.nlm.nih.gov/2942684/
  87. https://www.asecho.org/wp-content/uploads/2017/04/2017ValveStenosisGuideline.pdf
  88. https://www.escardio.org/static-file/Escardio/Subspecialty/EACVI/position-papers/eae-lang-chamber-quantification.pdf
  89. https://www.asecho.org/wp-content/uploads/2025/07/Left-Ventricular-Diastolic-Function.pdf
  90. https://ecgwaves.com/topic/assessment-of-diastolic-function-by-echocardiography/
  91. https://www.asecho.org/wp-content/uploads/2025/04/2015_Hypertension.pdf
  92. https://pubmed.ncbi.nlm.nih.gov/18369364/
  93. https://www.jacc.org/doi/10.1016/j.jacc.2022.11.022
  94. https://www.asecho.org/wp-content/uploads/2022/06/PIIS0894731722001407.pdf
  95. https://www.jacc.org/doi/abs/10.1016/j.jacc.2012.01.046
  96. https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.119.009678
  97. https://pubs.rsna.org/doi/abs/10.1148/rg.210122
  98. https://www.jacc.org/doi/10.1016/j.jcmg.2019.06.030
  99. https://www.jacc.org/doi/10.1016/j.jcmg.2017.09.005
  100. https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2997
  101. https://pubs.rsna.org/doi/10.1148/radiol.240516
  102. https://www.ahajournals.org/doi/10.1161/circheartfailure.113.000481
  103. https://www.ahajournals.org/doi/10.1161/01.hyp.0000178605.15028.ba
  104. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC10456116/
  106. https://pubmed.ncbi.nlm.nih.gov/29324968/
  107. https://www.ahajournals.org/doi/10.1161/HYP.0000000000000202
  108. https://pubmed.ncbi.nlm.nih.gov/17211252/
  109. https://pmc.ncbi.nlm.nih.gov/articles/PMC5541812/
  110. https://www.tobaccoinduceddiseases.org/Smoking-cessation-decreases-arterial-blood-pressure-in-hypertensive-smokers-A-subgroup%2C186853%2C0%2C2.html
  111. https://www.nejm.org/doi/full/10.1056/NEJMoa1009540
  112. https://pmc.ncbi.nlm.nih.gov/articles/PMC8502530/
  113. https://www.ahajournals.org/doi/10.1161/hypertensionaha.109.136655
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC11198320/
  115. https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Cardiomyopathy-Guidelines
  116. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001250
  117. https://www.nejm.org/doi/full/10.1056/NEJMoa2117597
  118. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067620
  119. https://pmc.ncbi.nlm.nih.gov/articles/PMC2662037/
  120. https://www.sciencedirect.com/science/article/pii/S0894731724002001
  121. https://jamanetwork.com/journals/jama/fullarticle/195319
  122. https://pubmed.ncbi.nlm.nih.gov/15326072/
  123. https://www.jacc.org/doi/10.1016/j.jacadv.2024.101210
  124. https://academic.oup.com/europace/article/27/5/euaf088/8116194
  125. https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.119.12684
  126. https://www.uptodate.com/contents/treatment-and-prognosis-of-heart-failure-with-preserved-ejection-fraction/print
  127. https://onlinelibrary.wiley.com/doi/full/10.4061/2011/495349
  128. https://heart.bmj.com/content/105/23/1832
  129. https://www.sciencedirect.com/science/article/abs/pii/S0009926016000891
  130. https://pmc.ncbi.nlm.nih.gov/articles/PMC3053573/
  131. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.043628
  132. https://www.sciencedirect.com/science/article/abs/pii/S0002914904012962
  133. https://www.ahajournals.org/doi/10.1161/cir.0000000000001356
  134. https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.122.20732
  135. https://pmc.ncbi.nlm.nih.gov/articles/PMC10584714/
  136. https://pmc.ncbi.nlm.nih.gov/articles/PMC5435124/
  137. https://www.who.int/tools/elena/interventions/sodium-cvd-adults
  138. https://www.ahajournals.org/doi/10.1161/cir.0b013e31820d0793
  139. https://pmc.ncbi.nlm.nih.gov/articles/PMC10095452/
  140. https://onlinelibrary.wiley.com/doi/10.1002/jgc4.1604
  141. https://www.heart.org/en/healthy-living/fitness/fitness-basics/aha-recs-for-physical-activity-in-adults
  142. https://www.medicalnewstoday.com/articles/daily-walking-can-lower-cardiovascular-diease-risk-even-in-people-who-sit-most-of-the-day
  143. https://www.jacc.org/doi/10.1016/j.jacc.2022.02.046
  144. https://www.nature.com/articles/s41598-023-50845-3
  145. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.042375
  146. https://pmc.ncbi.nlm.nih.gov/articles/PMC4839176/
Add your contribution
Related Hubs
User Avatar
No comments yet.